In order to improve the response to chemotherapy it seems reasonable that novel small-molecule GSTP1-targeted agents, which were developed to overcome resistance to treatment in ovarian, non-small-cell lung, breast, and colorectal cancers, can also be used to sensitize TCC tumor cells (Tew, 2005; Turella et al., 2005; Vergote et al., 2007). The gene discussed is GSTP1; the disease is neoplasm.